New drug combo shows promise in esophageal cancer trial

NCT ID NCT02962063

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 23 times

Summary

This study tests whether adding two immunotherapy drugs, durvalumab and tremelimumab, to standard chemoradiation is safe and effective for people with esophageal or gastroesophageal junction cancer. About 64 participants will receive the combination after initial chemotherapy. The goal is to see if this approach can improve tumor response without causing severe side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Nassau

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Rockville Centre

    Rockville Centre, New York, 11570, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.